Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Novavax Inc (NASDAQ:NVAX)

6.66
Delayed Data
As of Jun 24
 -0.25 / -3.62%
Today’s Change
4.08
Today|||52-Week Range
15.01
-20.62%
Year-to-Date
Brexit Bargains: 3 Clinical-Stage Biotechs to Buy
Jun 24 / MotleyFool.com - Paid Partner Content
Here's Why Novavax's Stock Could Double
Jun 14 / MotleyFool.com - Paid Partner Content
The Brexit Vote Is Crushing These 3 Clinical-Stage Biotech Stocks
Jun 24 / MotleyFool.com - Paid Partner Content
5 Top Stocks to Buy in June
Jun 13 / MotleyFool.com - Paid Partner Content

Today’s Trading

Previous close6.91
Today’s open6.53
Day’s range6.49 - 6.79
Volume6,381,334
Average volume (3 months)5,724,616
Market cap$1.8B
Dividend yield--
Data as of 4:00pm ET, 06/24/2016

Growth & Valuation

Earnings growth (last year)-62.16%
Earnings growth (this year)-60.19%
Earnings growth (next 5 years)0.00%
Revenue growth (last year)+18.24%
P/E ratioNM
Price/Sales60.70
Price/Book6.14

Competitors

 Today’s
change
Today’s
% change
OPHTOphthotech Corp-3.89-6.96%
RDUSRadius Health Inc-2.02-5.42%
BLUEbluebird bio Inc-1.48-3.50%
AXONAxovant Sciences Ltd-0.49-4.00%
Data as of 4:01pm ET, 06/24/2016

Financials

Next reporting dateAugust 3, 2016
EPS forecast (this quarter)-$0.25
Annual revenue (last year)$36.3M
Annual profit (last year)-$156.9M
Net profit margin-432.93%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
Stanley C. Erck
Senior Vice President-
Quality Operations
Robert Darius
Corporate headquarters
Gaithersburg, Maryland

Forecasts

Partner Offers

Search for Jobs